Hillhouse-backed cancer drug maker InnoCare moves closer to $620m STAR Market listing

Hillhouse-backed cancer drug maker InnoCare moves closer to $620m STAR Market listing

Source: Michael Longmire/Unsplash

InnoCare Pharma, a Chinese cancer drug developer backed by the Asian private equity (PE) major Hillhouse Capital Group, has moved closer to a planned secondary listing on Shanghai’s Nasdaq-style STAR Market that could raise about 4 billion yuan ($620.4 million).

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter